Advancing Precision Synthetic Biology To Meet Humankind’s Greatest Challenges
CB Therapeutics, is a biotechnology company fully-focused on the design, development, and manufacture of compounds and processes to meet four distinct challenges that face humankind. Our top tier, senior team of scientists see the problems of Mental Health, Physical Health & Wellness, Food Scarcity & Nutrition and Precision Fermentation as opportunities for our proprietary, proven, scalable, and sustainable, bio-manufacturing solutions to meet the needs of humankind.
Breakthrough Science Powered by Yeast
We have developed a cutting-edge proprietary yeast platform that enhances natural metabolic processes through precision fermentation to produce a variety of compounds, from small chemical analogs to bio-identical molecules that exactly match their counterparts in nature. The clear advantage for our efficient and sustainable production method is the rapid delivery of pure, consistent, and reliable molecules for our customers.
Robust Production Capabilities
CB Therapeutics is trailblazing the creation of new opportunities for precision synthetic biology by efficiently standardizing and scaling the production of the highest quality psychedelic therapeutics, cannabinoids, animal-free food ingredients, and many more high value molecules. We are already supplying, or in negotiations to supply, such diverse industries as neuroscience, clinical research, nutraceutical, cannabis, cosmetics, and the food and beverage markets.
We Are the Future for Precision Fermentation
CB Therapeutics was purpose-built to create the new innovations and methods to sustainably manufacture tomorrow’s products to meet the challenge of a changing world. We are building a state-of-the-art precision fermentation bio-manufacturing facility adjacent to our labs, so we can begin to meet customer demand for our products in the commercial markets.
CB Therapeutics in the News
People are paying attention to us.
May 19, 2022
To tackle sustainable food and active ingredient manufacturing, CB Therapeutics is developing eco-conscious solutions through precision fermentation
CARLSBAD, Calif., July 21, 2022 -- CB Therapeutics (the "Company"), a biosynthesis company focused on creating ethically-produced, environmentally-friendly products for human health, has successfully developed various food tech prototypes using its next-gen synbio and precision fermentation platform. Now, the Company is looking for partnerships in the food technology and active ingredient spaces that align with its value propositions.
May 19, 2022
CB Therapeutics’ Business Development Lead, Tiffany Hurd, is Further Bridging the Gap Between Pharma and Psychedelics
CARLSBAD, Calif., June 20, 2022 (GLOBE NEWSWIRE) — CB Therapeutics (the "Company"), a biosynthesis company focused on creating ethically-produced, environmentally-friendly products for human health, welcomes a new member of the team who is focused on growth and sustainability.
April 25, 2022
CB Therapeutics rapidly expands cellular agriculture capabilities at new facility
CARLSBAD, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- CB Therapeutics (the “Company”), a biosynthesis company focused on creating ethically-produced, environmentally-friendly products for human health, is celebrating a move to an expanded laboratory, which will serve to
increase its research compound production footprint.
December 20, 2021
Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics today announces the appointments of Dr. Stephen Wright and Dr. Brian Barnett to its newly formed Medical Advisory Board.
December 9, 2021
CB Therapeutics and atai Life Sciences launch TryptageniX to sustainably supply and develop clinically relevant compounds to tackle the growing mental health crisis
SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- CB Therapeutics, a biosynthesis company focused on creating ethical and environmentally-friendly products to improve mental health and increase healthspan, believes their partnership with atai Life Sciences will help to meet the growing unmet needs of patients with mental health conditions.
August 24, 2021
CB Therapeutics Achieves Another Breakthrough with the Biosynthesis of DMT and Related Tryptamine-based Compounds
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is happy to announce that it has been awarded two more patents for the novel methods of production of high value molecules using cutting-edge biosynthesis technologies. These patents (11,041,002B1 and 10,988,785B1) cover inventions on cellular agriculture breakthroughs for producing cannabinoids and precursors to various other compounds...
May 10, 2021
CB Therapeutics Closes on Oversubscribed Series A
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics Inc., the leading synthetic biology company focused on the development and biosynthetic production of existing and novel tryptamines and cannabinoids, is pleased to announce that it has closed an oversubscribed Series A funding round, filled entirely by re.Mind Capital, a fund launched by the psychedelics kingmaker, Christian Angermayer within Apeiron, his family office…
September 23, 2020
CB Therapeutics Achieves Major Breakthroughs in Downstream Processing and Purification, Paving the Way for Low-cost Cannabinoids, Tryptamines, and Their Analogs
SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics Inc., has successfully refined its in-house downstream processing, allowing for 99.6% pure CBC. a rare cannabinoid molecule found in trace quantities in cannabis and hemp. Using these patent-pending techniques, CB Therapeutics is able to drive down the cost of purification in parallel with increasing the purity to over 99%, considered a major breakthrough for any type of purification process…